000095957 001__ 95957 000095957 005__ 20230914083240.0 000095957 0247_ $$2doi$$a10.3332/ECANCER.2019.998 000095957 0248_ $$2sideral$$a116394 000095957 037__ $$aART-2020-116394 000095957 041__ $$aeng 000095957 100__ $$aWalker, J. 000095957 245__ $$aHighlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention 000095957 260__ $$c2020 000095957 5060_ $$aAccess copy available to the general public$$fUnrestricted 000095957 5203_ $$aAt the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit. 000095957 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000095957 592__ $$a0.707$$b2020 000095957 593__ $$aOncology$$c2020$$dQ3 000095957 593__ $$aCancer Research$$c2020$$dQ3 000095957 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000095957 700__ $$aCattaneo, M. 000095957 700__ $$aBadimon, L. 000095957 700__ $$aAgnelli, G. 000095957 700__ $$aChan, A.T. 000095957 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza 000095957 700__ $$aRocca, B. 000095957 700__ $$aRothwell, P. 000095957 700__ $$aPatrignani, P. 000095957 700__ $$aLangley, R. 000095957 700__ $$aVilahur, G. 000095957 700__ $$aCosentino, F. 000095957 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000095957 773__ $$g14, 998 (2020), [24 pp]$$tecancermedicalscience$$x1754-6605 000095957 8564_ $$s633305$$uhttps://zaguan.unizar.es/record/95957/files/texto_completo.pdf$$yVersión publicada 000095957 8564_ $$s441409$$uhttps://zaguan.unizar.es/record/95957/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000095957 909CO $$ooai:zaguan.unizar.es:95957$$particulos$$pdriver 000095957 951__ $$a2023-09-13-10:48:16 000095957 980__ $$aARTICLE